GSK terminates SIRT1 activator following renal concerns
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is terminating the development of SRT501, a formulation of resveratrol, which it acquired when it bought the biotech company Sirtris in 2008 for $720 million.